贝伐单抗联合培美曲塞和顺铂化疗方案治疗晚期肺腺癌的疗效及安全性  

Clinical Efficacy and Safety of Bevacizumab Combined with Pemetrexide and Cisplatin Chemotherapy in Treatment of Advanced Lung Adenocarcinoma

作　　者：杨俊红[1] 王洪海[1] 李志英[1] YANG Junhong;WANG Honghai;LI Zhiying(Dept.of Oncology,Anyang Oncology Hospital,Henan Anyang 455000,China)

机构地区：[1]安阳市肿瘤医院肿瘤内科,河南安阳455000

出　　处：《中国医院用药评价与分析》2018年第9期1220-1222,共3页Evaluation and Analysis of Drug-use in Hospitals of China

摘　　要：目的:探讨贝伐单抗联合培美曲塞和顺铂化疗方案治疗晚期肺腺癌的疗效及安全性。方法:选取2015年8月至2017年8月安阳市肿瘤医院收治的晚期肺腺癌患者150例,以随机数字表法分为观察组和对照组,每组75例。对照组患者给予培美曲塞联合顺铂化疗,观察组患者在对照组的基础上加用贝伐单抗。比较两组患者的疾病控制情况、不良反应发生情况及生活质量改善效果的差异。结果:观察组患者的疾病控制率为93.33%(70/75),明显高于对照组的74.67%(56/75),差异有统计学意义(P<0.05);观察组患者高血压发生率明显高于对照组,差异有统计学意义(P<0.05);观察组患者认知、情绪评分明显高于对照组,呼吸困难、疼痛及疲劳评分明显低于对照组,差异均有统计学意义(P<0.05)。结论:贝伐单抗联合培美曲塞和顺铂化疗方案对晚期肺腺癌患者的疾病发展具有良好的控制效果,可有效改善其生活质量,但在治疗期间应注意高血压的发生。OBJECTIVE： To probe into the efficacy and safety of bevacizumab combined with pemetrexide and cisplatin chemotherapy in treatment of advanced lung adenocarcinoma. METHODS： 150 patients with advanced lung adenocarcinoma admitted into Anyang Oncology Hospital from Aug. 2015 to Aug. 2017 were extract to be divided into observation group and control group via the random number table,with 75 cases in each. The control group was given pemetrexed combined with cisplatin chemotherapy,while the observation group additionally received bevacizumab based on the control group. The disease control situation,occurrence of adverse drug reactions and improvement of life quality of two groups were compared. RESULTS： The disease control rate of observation group was 93. 33%（ 70/75）,significantly higher than that of control group [74. 67%（ 56/75） ],with statistically significant difference（ P〈0. 05）. The incidence of hypertension of observation group was significantly higher than that of control group,with statistically significant difference（ P〈0. 05）. The cognitive and emotional scores of observation group were significantly higher than those of the control group; and the dyspnea,pain and fatigue scores of observation group were significantly lower than control group,the differences were statistically significant（ P〈0. 05）. CONCLUSIONS：Bevacizumab combined with pemetrexed and cisplatin chemotherapy has a good control effects on the disease development of patients with advanced lung adenocarcinoma,which can effectively improve the quality of life,however,attention should be paid to the occurrence of hypertension during treatment.

关 键 词：肺腺癌 贝伐单抗 培美曲塞 顺铂 近期疗效 

分 类 号：R979.1[医药卫生—药品]